Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety of Topical MSC Secretome for Ocular Surface Disease
NCT05204329Phase 1Completed
- Sponsor
- University of Illinois Chicago
- Start
- Jan 2024
- Primary completion
- Nov 2024
- Modality
- Lipid-based Nanoparticles
- Countries
- 1
01
Overview
Phase 1, open-label trial of Allogeneic bone marrow-derived mesenchymal stromal cell secretome in corneal epithelial disease (3 arms), sponsored by University of Illinois Chicago. Primary endpoints: Dose Limiting Toxicities at 28 days and Corneal Epithelial Integrity at 28 days. Started Jan 2024; status: completed.
02
Drugs
Allogeneic bone marrow-derived mesenchymal stromal cell secretome
03
Conditions
corneal epithelial disease
Beyond the preview
Go deeper on NCT05204329.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05204329.